MsA’s suppression of BChE, an enzyme overexpressed in late-stage AD and contributing to Aβ deposition and cognitive decline, represents a strategically important therapeutic intervention that has not been thoroughly documented for comparator compounds. The gene discussed is BCHE; the disease is Alzheimer disease.